Literature DB >> 11846798

Characteristics of binding of insulin-like growth factor (IGF)-I and IGF-II analogues to the type 1 IGF receptor determined by BIAcore analysis.

Briony E Forbes1, Perry J Hartfield, Kerrie A McNeil, Kathy H Surinya, Steven J Milner, Leah J Cosgrove, John C Wallace.   

Abstract

Insulin-like growth factor (IGF) binding to the type 1 IGF receptor (IGF1R) elicits mitogenic effects, promotion of differentiation and protection from apoptosis. This study has systematically measured IGF1R binding affinities of IGF-I, IGF-II and 14 IGF analogues to a recombinant high-affinity form of the IGF1R using BIAcore technology. The analogues assessed could be divided into two groups: (a) those designed to investigate binding of IGF-binding protein, which exhibited IGF1R-binding affinities similar to those of IGF-I or IGF-II; (b) those generated to probe IGF1R interactions with greatly reduced IGF1R-binding affinities. The relative binding affinities of IGF-I analogues and IGF-I for the IGF1R determined by BIAcore analysis agreed closely with existing data from receptor-binding assays using cells or tissue membranes, demonstrating that BIAcore technology is a powerful tool for measuring affinities of IGFs for IGF1R. In parallel studies, IGF1R-binding affinities were related to ability to protect against serum withdrawal-induced apoptosis in three different assays including Hoechst 33258 staining, cell survival, and DNA fragmentation assays using the rat pheochromocytoma cell line, PC12. In this model system, IGF-I and IGF-II at low nanomolar concentrations are able to prevent apoptosis completely. We conclude that ability to protect against apoptosis is directly related to ability to bind the IGF1R.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11846798     DOI: 10.1046/j.0014-2956.2001.02735.x

Source DB:  PubMed          Journal:  Eur J Biochem        ISSN: 0014-2956


  12 in total

Review 1.  Heterotrimeric G proteins and the single-transmembrane domain IGF-II/M6P receptor: functional interaction and relevance to cell signaling.

Authors:  C Hawkes; A Amritraj; R G Macdonald; J H Jhamandas; S Kar
Journal:  Mol Neurobiol       Date:  2007-06       Impact factor: 5.590

2.  Determination of peptide-surface adsorption free energy for material surfaces not conducive to SPR or QCM using AFM.

Authors:  Aby A Thyparambil; Yang Wei; Robert A Latour
Journal:  Langmuir       Date:  2012-03-20       Impact factor: 3.882

3.  Precise mapping of an IGF-I-binding site on the IGF-1R.

Authors:  Mehrnaz Keyhanfar; Grant W Booker; Jonathan Whittaker; John C Wallace; Briony E Forbes
Journal:  Biochem J       Date:  2007-01-01       Impact factor: 3.857

Review 4.  Inhibition of the insulin-like growth factor-1 receptor (IGF1R) tyrosine kinase as a novel cancer therapy approach.

Authors:  Rongshi Li; Alan Pourpak; Stephan W Morris
Journal:  J Med Chem       Date:  2009-08-27       Impact factor: 7.446

5.  Potentiation of growth factor signaling by insulin-like growth factor-binding protein-3 in breast epithelial cells requires sphingosine kinase activity.

Authors:  Janet L Martin; Mike Z Lin; Eileen M McGowan; Robert C Baxter
Journal:  J Biol Chem       Date:  2009-07-25       Impact factor: 5.157

6.  The pro-forms of insulin-like growth factor I (IGF-I) are predominant in skeletal muscle and alter IGF-I receptor activation.

Authors:  Julia Durzyńska; Anastassios Philippou; Becky K Brisson; Michelle Nguyen-McCarty; Elisabeth R Barton
Journal:  Endocrinology       Date:  2013-02-13       Impact factor: 4.736

7.  Structure and functional analysis of the IGF-II/IGF2R interaction.

Authors:  James Brown; Carlie Delaine; Oliver J Zaccheo; Christian Siebold; Robert J Gilbert; Gijs van Boxel; Adam Denley; John C Wallace; A Bassim Hassan; Briony E Forbes; E Yvonne Jones
Journal:  EMBO J       Date:  2007-11-29       Impact factor: 11.598

8.  A Loss of Epigenetic Control Can Promote Cell Death through Reversing the Balance of Pathways in a Signaling Network.

Authors:  Kiran G Vanaja; Winston Timp; Andrew P Feinberg; Andre Levchenko
Journal:  Mol Cell       Date:  2018-09-20       Impact factor: 17.970

9.  Targeting the insulin-like growth factor pathway in rhabdomyosarcomas: rationale and future perspectives.

Authors:  Ana Sofia Martins; David Olmos; Edoardo Missiaglia; Janet Shipley
Journal:  Sarcoma       Date:  2011-03-03

Review 10.  Therapeutic Targeting of the IGF Axis.

Authors:  Eliot Osher; Valentine M Macaulay
Journal:  Cells       Date:  2019-08-14       Impact factor: 6.600

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.